Application of Artificial Intelligence to Plasma Metabolomics Profiles to Predict Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer
Ehsan Irajizad, Ranran Wu, Jody V. Vykoukal, Eunice Murage, Rachelle Spencer, Jennifer B. Dennison, Stacy L. Moulder, Elizabeth E. Ravenberg, Bora Lim, Jennifer K. Litton, Debu Tripathym, Vicente Valero, Senthil Damodaran, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Abenaa M. Brewster, Banu Arun, James P. Long, Kim‐Anh Do, Samir Hanash, Johannes F. Fahrmann
Abstract
There is a need to identify biomarkers predictive of response to neoadjuvant chemotherapy (NACT) in triple-negative breast cancer (TNBC). We previously obtained evidence that a polyamine signature in the blood is associated with TNBC development and progression. In this study, we evaluated whether plasma polyamines and other metabolites may identify TNBC patients who are less likely to respond to NACT. Pre-treatment plasma levels of acetylated polyamines were elevated in TNBC patients that had moderate to extensive tumor burden (RCB-II/III) following NACT compared to those that achieved a complete pathological response (pCR/RCB-0) or had minimal residual disease (RCB-I). We further applied artificial intelligence to comprehensive metabolic profiles to identify additional metabolites associated with treatment response. Using a deep learning model (DLM), a metabolite panel consisting of two polyamines as well as nine additional metabolites was developed for improved prediction of RCB-II/III. The DLM has potential clinical value for identifying TNBC patients who are unlikely to respond to NACT and who may benefit from other treatment modalities.